Incidence and risk of post-COVID-19 thromboembolic disease and the impact of aspirin prescription; nationwide observational cohort at the US Department of Veteran Affairs
Findings demonstrated that preexisting aspirin prescription prior to COVID-19 diagnosis was associated with significantly decreased risk of venous thromboembolism and pulmonary embolism but increased risk of acute arterial disease. The risk of arterial disease may be associated with increased COVID-19 prothrombotic effects superimposed on preexisting chronic cardiovascular disease for which aspirin was already prescribed. Prospective clinical trials may help to further assess the efficacy of aspirin use prior to COVID-19 diagnosis for the prevention of post-COVID-19 thromboembolic disorders.
Authors
- Thomas F. Osborne (ORCID: https://orcid.org/0000-0002-8896-2487)
- George N. Ioannou (ORCID: https://orcid.org/0000-0003-1796-8977)
- Anna Ware (ORCID: https://orcid.org/0000-0003-3333-7833)
- Edward J. Boyko (ORCID: https://orcid.org/0000-0002-3695-192X)
- Zachary P Veigulis (ORCID: https://orcid.org/0000-0002-9026-1604)
- Peter Hoover (ORCID: https://orcid.org/0000-0001-6235-3141)
- Terri L. Blumke (ORCID: https://orcid.org/0009-0006-4945-3571)
Institutions
- University of Iowa (US)
- University of Washington (US)
- VA Palo Alto Health Care System (US)
- VA Puget Sound Health Care System (US)
- Seattle Epidemiologic Information and Research Center (US)
- National Center for PTSD (US)
- Stanford University (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1371/journal.pone.0302612
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Veterans Affairs